Publications that relate characteristics of donors to renal function of recipients are reviewed. Most publications report retrospective observations that relate outcomes to donor variables that cannot be altered during donor care. Factors that can be altered in adult donors in an effort to improve recipients' outcomes include urine output and creatinine level. Increasing urine output to more than 100 mL/h, at least during the hour before explantation, and returning the creatinine level to match its serum concentration when the patient was admitted can improve outcomes. Ways of accomplishing those goals during donor care are discussed, with emphasis on support of renal blood flow.
Get full access to this article
View all access options for this article.
References
1.
RamosEAounSHarmonWE. Expanding the donor pool: Effect on graft outcome. J Am Soc Nephrol.2002;13:2590–2599.
2.
ModlinCSGoldfarbDANovickAC. The use of expanded criteria cadaver and live donor kidneys for transplantation. Urol Clin North Am.2001;28:687–707.
3.
SwansonSJHypoliteIOAgodoaLYC. Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant.2002;2:68–75.
4.
Goldfarb-RumyantzevASScandlingJDPappasLSmoutRJHornS. Prediction of 3-yr cadaveric graft survival based on pre-transplant variables in a large national dataset. Clin Transplant.2003;17:485–497.
5.
PortFKBragg-GreshamJLMetzgerRA. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation.2002;74:1281–1286.
6.
AlexanderJWBennettLEBreenTJ. Effect of donor age on outcome of kidney transplantation. Transplantation.1994;57:871–876.
7.
ChertowGMMilfordELMackenzieHSBrennerBM. Antigen-independent determinants of cadaveric kidney transplant failure. JAMA.1996;276:1732–1736.
8.
KouliFMorrellCHRatnerLEKrausES. Impact of donor/recipient traits independent of rejection on long-term renal function. Am J Kidney Dis.2001;37:356–365.
9.
PfaffWWHowardRJPattonPRAdamsVRRosenCBReedAI. Delayed graft function after renal transplantation. Transplantation.1998;65:219–223.
10.
MatasAJGillinghamKJHumarADunnDLSutherlandDENajarianJS. Immunologic and nonimmunologic factors: Different risks for cadaver and living donor transplantation. Transplantation.2000;69:54–58.
11.
CosioFGQiuWHenryML. Factors related to the donor organ are major determinants of renal allograft function and survival. Transplantation.1996;62:1571–1576.
12.
OjoAOLeichtmanABPunchJD. Impact of pre-existing donor hypertension and diabetes mellitus on cadaveric renal transplant outcomes. Am J Kidney Dis.2000;36:153–159.
13.
KeitelEMichelonTdos SantosAF. Renal transplants using expanded cadaver donor criteria. Ann Transplant.2004;9:23–24.
14.
CeckaM. Clinical outcome of renal transplantation: Factors influencing patient and graft survival. Surg Clin North Am.1998;78:133–148.
15.
RatnerLEJosephVZibariG. Transplantation of kidneys from hypertensive cadaveric donors. Transplant Proc.1995;27:989–990.
16.
BertoniEZanazziMRosatiA. Fate of kidneys retrieved from the same donor and grafted into different recipients: Do donor-related factors influence the graft outcome?Transplant Proc.1997;29:125–126.
17.
Meier-KriescheHUCibrikDMOjoAO. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc.2002;50:14–17.
18.
LucasBAVaughnWKSpeesEKSanfilippoF. Identification of donor factors predisposing to high discard rates of cadaver kidneys and increased graft loss within one year post transplantation: SEOPF 1997–1982. Transplantation.1987;43:253–258.
19.
TerasakiPIGjertsonDWCeckaJMTakemotoSChoYW. Significance of the donor age effect on kidney transplants. Clin Transplant.1997;11:366–372.
20.
GrekasDAlivanisPDerveniotisVPapoulidouFKaklamanisNTourkantonisA. Influence of donor data on graft function after cadaveric renal transplantation. Transplant Proc.1996;28:2957–2958.
21.
BattagliaMDitonnoPSelvaggioO. Kidney transplants from infected donors: Our experience. Transplant Proc.2004;36:491–492.
22.
ZibariGBLipkaJZizziHAbreoKDJacobbiLMcDonaldJC. The use of contaminated donor organs in transplantation. Clin Transplant.2000;14:397–400.
23.
SzczechLAColadonatoJAOwenWF. Study designs and their potential influence on conclusions. Semin Dial.2002;15:207–211.
24.
SzczechLAColadonatoJAOwenWF. Key concepts in biostatistics: Using statistics to answer the question “Is there a difference?”Semin Dial.2002;15:347–351.
25.
PownerDJCrommettJW. Advanced assessment of hemodynamic parameters during donor care. Prog Transplant.2003;13:249–257.
26.
PownerDJDarbyJM. Management of variations in blood pressure during care of organ donors. Prog Transplant.2000;10:25–32.
27.
PownerDJDarbyJMKellumJA. Proposed treatment guidelines for donor care. Prog Transplant.2004;14:16–28.
28.
PownerDJKellumJADarbyJM. Abnormalities in fluids, electrolytes, and metabolism of organ donors. Prog Transplant.2000;10:88–96.
29.
DebelakLPollakRReckardC. Arginine vasopressin versus desmopressin for the treatment of diabetes insipidus in the brain dead organ donor. Transplant Proc.1990;22:351–352.
30.
GuesdeRBarrouBLeblancI. Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet.1998;352:1178–1181.
31.
IchaiCSoubielleJCarlesMGiuntiCGrimaudD. Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: A single-blind randomized study. Crit Care Med.2000;28:921–928.
32.
MaleckWHPiperSNKoetterKP. Use of dopamine in acute renal failure. Crit Care Med.2002;30:1934–1936.
33.
Australian and New Zealand Intensive Care Society Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomized trial. Lancet.2000;356:2139–2143.
34.
DebaveyeYAVan den BergheGH. Is there still a place for dopamine in the modern intensive care unit?Anesth Analg.2004;98:461–468.
35.
KellumJADeckerJM. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med.2001;29:1526–1531.
36.
CittanovaMLLeblancILegendreCHMouquetCRiouBCoriatP. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet.1996;348:1620–1622.
37.
CittanovaMLMavreJRiouBCoriatP. Long-term follow-up of transplanted kidneys according to plasma volume expander of kidney donors. Intensive Care Med.2001;27:1830.
38.
SchortgenFLacheradeJCBruneelF. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomized study. Lancet.2001;357:911–916.
39.
deJongeELeviMBullerHRBerendsFKeseciogluJ. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethylstarch (HES 200/0.56) in healthy human subjects. Intensive Care Med.2001;27:1825–1829.
40.
StraussRGPennellBJStumpDC. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion.2002;42:27–36.
41.
DemanAPeetersPSennesaelJ. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: A retrospective, multicentre analysis. Nephrol Dial Transplant.1999;14:1517–1520.
42.
BoldtJ. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet.2001;358:581–583.
43.
NeffTADoelbergMJungheinrichCSauerlandASpahnDRStockerR. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg.2003;96:1453:1459.
44.
KopkoPMMarshallCSMacKenzieMRHollandPVPopovskyMA. Transfusion-related acute lung injury: Report of a clinical look-back investigation. JAMA.2002;287:1968–1971.
45.
GazmuriRJShakeriSA. Blood transfusion and the risk of nosocomial infection: An underreported complication?Crit Care Med.2002;30:2389–2391.
46.
PreiksaitisJK. Prevention of transfusion-acquired CMV infection: Is there a role for NAT?Transfusion.2003;43:302–305.
47.
WeilMH. Blood transfusions. Crit Care Med.2003;31:2397–2398.
48.
NapolitanoLMCorwinHL. Efficacy of blood transfusion in the critically ill: Does age of blood make a difference?Crit Care Med.2004;32:594–595.
49.
ZallenGMooreEECieslaDJBrownMBifflWLSillimanCC. Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2. Shock.2000;13:29–33.
50.
HebertPCWellsGBlajchmanMA. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med.1999;340:409–417.
51.
HebertPCYetisirEMartinC. Is a low transfusion safe in critically ill patients with cardiovascular diseases?Crit Care Med.2001;29:227–234.
52.
CreteurJVincentJL. Hemoglobin solutions. Crit Care Med.2003;31(12 suppl):S698–S707.
53.
MooreFAMcKinleyBAMooreEE. The next generation in shock resuscitation. Lancet.2004;363:1988–1996.
54.
SchnuellePBergerSDe BoerJPersijnGVan Der WoudeFJ. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation.2001;72:455–463.
55.
SchnuellePLorenzDMuellerATredeMVan Der WoudeFJ. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int.1999;56:738–746.
56.
DecauxAAlexandreLEschwegeP. Does epinephrine administered in donor resuscitation influence graft renal function in the recipient?Transplant Proc.1996;28:2889.
